Skip to main content

Table 3 Comparison of the proportion of the selected chemotherapy regimens, dose-reduction, and skip administration

From: A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study

  All patients Cisplatin-eligible
(eGFR ≥60 mL/min/1.73m2)
Cisplatin-ineligible
(eGFR < 60 mL/min/1.73 m2)
Cisplatin-eligible
(n = 119)
Cisplatin-ineligible
(n = 125)
p Bilateral
functioning
kidneys
(n = 83)
Solitary
functioning
kidney
(n = 36)
p Bilateral
functioning
kidneys
(n = 45)
Solitary
functioning
kidney
(n = 80)
p
Chemotherapy GC 48 (40.3%) 55 (44.0%) 0.56 35 (42.2%) 13 (36.2%) 0.530 24 (53.3%) 31 (38.8%) 0.160
MVAC 52 (43.6%) 46 (36.8%) 0.27 37 (44.6%) 15 (41.6%) 0.760 14 (31.1%) 32 (40.0%) 0.110
MEC 16 (13.4%) 19 (15.2%) 0.70 9 (10.8%) 7 (19.4%) 0.210 4 (8.9%) 15 (18.7%) 0.140
Gemcitabine + Cisplatin + Docetaxel 3 (2.5%) 5 (4.0%) 0.51 2 (2.4%) 1 (2.8%) 0.900 3 (6.7%) 2 (2.5%) 0.850
Cisplatin dose reduction
 all courses Yes 10 (8.4%) 42 (33.6%) < 0.001 6 (7.2%) 4 (11.1%) 0.480 16 (35.5%) 26 (32.5%) 0.730
 1st course Yes 9/119 (7.5%) 48/125 (38.4%) < 0.001 6/83 (7.2%) 3/36 (8.3%) 0.834 16/45 (35.5%) 32/80 (39.9%) 0.623
99-80% 8/119 (6.7%) 15/125 (12.0%) 0.158 5/83 (6.0%) 3/36 (8.3%) 0.644 5/45 (11.1%) 10/80 (12.5%) 0.810
<  80% 1/119 (0.8%) 33/125 (26.4%) < 0.001 1/83 (1.2%) 0/36 (0.0%) 0.508 11/45 (24.4%) 22/80 (27.5%) 0.709
 2nd course Yes 8/104 (7.7%) 39/110 (35.3%) < 0.001 5/72 (8.3%) 3/32 (9.3%) 0.667 13/42 (30.8%) 26/68 (38.1%) 0.437
99-80% 7/104 (6.7%) 9/110 (8.1%) 0.686 4/72 (6.9%) 3/32 (9.3%) 0.473 2/42 (4.7%) 7/68 (10.2%) 0.303
<  80% 1/104 (1.0%) 30/110 (27.2%) < 0.001 1/72 (1.4%) 0/32 (0.0%) 0.500 11/42 (26.1%) 19/68 (27.9%) 0.841
 3rd course Yes 4/81 (4.9%) 23/82 (28.0%) < 0.001 2/54 (3.8%) 2/27 (7.4%) 0.468 6/24 (24.9%) 17/58 (29.2%) 0.690
99-80% 3/81 (3.7%) 7/82 (8.5%) 0.198 1/54 (1.9%) 2/27 (7.4%) 0.212 1/24 (4.1%) 6/58 (10.3%) 0.362
<  80% 1/81 (1.2%) 16/82 (19.5%) < 0.001 1/54 (1.9%) 0/27 (0.0%) 0.476 5/24 (20.8%) 11/58 (18.9%) 0.846
 4th course Yes 2/59 (3.4%) 15/59 (25.4%) < 0.001 0/39 (0.0%) 2/20 (10.0%) 0.044 4/20 (20.0%) 12/39 (30.7%) 0.378
99-80% 2/59 (3.4%) 6/59 (10.2%) 0.142 0/39 (0.0%) 2/20 (10.0%) 0.044 1/20 (5.0%) 5/39 (12.8%) 0.346
<  80% 0/59 (0.0%) 9/59 (15.2%) < 0.001 0/39 (0.0%) 0/20 (0.0%) 1.000 3/20 (15.0%) 7/39 (17.9%) 0.775
Skip
 all courses Yes 65 (54.6%) 70 (56.0%) 0.83 49 (59.0%) 16 (44.4%) 0.140 23 (51.1%) 47 (58.8%) 0.400
No 54 (45.3%) 55 (44.0%)   34 (40.9%) 20 (55.6%)   22 (48.9%) 33 (41.2%)  
 1st course day 8 8 (6.7%) 15 (12.0%) 0.16 7 (8.4%) 1 (2.7%) 0.250 4 (8.9%) 11 (13.7%) 0.420
day 15 54 (45.3%) 54 (43.2%) 0.73 40 (48.1%) 14 (38.9%) 0.340 17 (37.7%) 37 (46.3%) 0.350
day 22 8 (6.7%) 13 (10.4%) 0.30 6 (7.2%) 2 (5.6%) 0.730 4 (4.4%) 9 (11.3%) 0.680
  1. BC bladder cancer, UTUC upper urinary tract urothelial cancer
\